EarningsQ3 2026 Earnings Report
MX:ICLRN Q3 2026 EPS Results
Actual EPS$49.97
Consensus EPS$49.16
Beat/MissBeat by +$0.81
One Year Ago EPS$62.18
MX:ICLRN Q3 2026 Revenue Results
Actual Revenue$38.04B
Expected Revenue$37.81B
Beat/MissBeat by +$229.37M
YoY Revenue Growth-2.86%
Earnings Announcement Details
QuarterQ3 2026
Date10/27/2026
TimeAfter Close
Conference CallTuesday, October 27, 2026
MX:ICLRN Upcoming Earnings
Icon's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:ICLRN Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was strongly positive overall. Commercial momentum, record net bookings, sustained book-to-bill performance, margin expansion, cost discipline, cash generation, technology productivity gains, and constructive demand outweighed the year-over-year revenue decline, pass-through volatility, foreign exchange headwind, and expected fourth-quarter SG&A increase.Company Guidance
Adjusted EBITDA and EPS Growth
Adjusted EBITDA increased 3% sequentially to $337 million, while adjusted EBITDA margin expanded by 70 basis points to 16.6%. Adjusted EPS was $2.66, an increase of 4% compared with Q2.
Gross Margin Expansion
Gross margin improved by 90 basis points sequentially to 24.7%, driven by improved business mix, a better direct fee mix, operating cost management, and measures taken in the first half beginning to impact the second half.
Record Net Business Wins
Gross business wins increased 27% year-over-year and 3% sequentially. Net business wins reached a record $3.15 billion, up 51% year-over-year, producing a net book-to-bill ratio of 1.56x.
Sustained Book-to-Bill Momentum
ICON recorded its fourth consecutive quarter with net book-to-bill above 1.3x. Trailing 12-month direct fee book-to-bill was 1.3x, approximately 30% higher than the preceding 12-month period, which was closer to 1.0x.
Strong Cash Generation and Share Repurchases
The company generated $302 million of free cash flow in Q3, including $340 million of cash from operating activities and $38 million of capital expenditure. ICON repurchased $400 million of shares during the quarter at an average price of $170 per share.
New Share Repurchase Authorization
The Board approved a new $750 million share repurchase authorization, which management said underscored its confidence in the business and commitment to shareholder returns.
Refinancing and Capital Flexibility
ICON completed a $2.15 billion investment-grade bond issuance. The proceeds were used to repay the senior secured term loan, redeem the May 2027 notes, and repay the bridge secured credit facility. Management said the balance sheet and free cash flow provide flexibility for organic investment, selective M&A, and shareholder returns.
Improved Cost Discipline
Adjusted SG&A expense declined to $163 million, or 8.1% of revenue, compared with $179 million, or 8.6% of revenue, in Q3 of the prior year. Management attributed the performance to strong cost discipline and phasing of investments.
Strength Across Large Pharma
Large pharma remained a source of continued strength, with strong contributions across full service and FSP. ICON expanded an existing alliance through the addition of a large-scale pharmacovigilance portfolio, and multi-year FSP renewals reflected customers' continued preference for flexible partnership models.
Midsized Pharma and Biotech Expansion
Opportunity flow among midsized pharma continued to strengthen, with new and expanded partnerships during the quarter. In biotech, demand remained constructive, ICON is now covering 30% more companies than one year ago, and the company added three preferred partnerships with enterprise biotech customers, including a four-year sole-provider arrangement spanning all phases of development.
Robust Demand Environment
Management described demand as robust in large pharma FSO and said opportunity flow was up high single digits on a trailing 12-month basis across the business. ICON is working at significant levels with 28 of the top 30 pharma companies and saw strong demand across FSP, laboratories, evidence generation, and other ancillary services.
AI and Technology Productivity Gains
SDTM programming agents in production since February reduced programming cycle times by 28% on in-scope studies. Study startup throughput increased about 30% year-to-date, and SmartDraft reduced site contracting cycle time by 10% over the year, with near-term targets for an additional 20% reduction. ICON also said its MRIdian monitoring agent continues to resonate with customers.
Continued Investment in Therapeutic Expertise
ICON is continuing targeted investments in therapeutic and scientific expertise, including patient advocacy and radioligand therapy capabilities in oncology, as well as expanded capacity in endocrinology and neurology.
Positive 2026 and 2027 Outlook Indicators
The company narrowed its 2026 guidance range and said current trends support positive momentum in revenue and earnings for Q4. Management said four strong quarters of bookings, a growing backlog, and an improving business mix provide a clearer view of revenue growth and meaningful earnings progression. Without providing formal 2027 guidance, management said mid-single-digit revenue expansion and potentially higher-single-digit earnings expansion are reasonable propositions with good execution.
Full-Year Margin Expectations Maintained
Management reiterated that full-year 2026 adjusted EBITDA margin is expected to be in the region of 16% to 16.5%, depending largely on fourth-quarter pass-through activity, while remaining on track operationally and for progression in earnings dollars.
Selective M&A Strategy
ICON said capital allocation will include continued shareholder returns, organic investment in strategic capabilities, and selective M&A where timing, valuation, and strategic fit are appropriate. Management emphasized that potential acquisitions would need to be in potentially high-growth or high-margin areas with a strong strategic fit, rather than transformational M&A for scale alone.
MX:ICLRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed